Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milciclib in Unresectable or Metastatic Hepatocellular Carcinoma
NCT03109886Phase 2Completed
- Sponsor
- Tiziana Life Sciences
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of milciclib in hepatocellular carcinoma (HCC), sponsored by Tiziana Life Sciences. Primary endpoint: Overall Safety Profile at Day 180. Started Jul 2017; status: completed.
02
Drugs
milciclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03109886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109886.